Determination of Related Substances in Lapatinib Ditosylate Tablets by HPLC

LIU Jun-hua, LIANG Xing-hui,WANG Bin-rong

Chinese Pharmaceutical Journal ›› 2013, Vol. 48 ›› Issue (8) : 644-648.

PDF(1008 KB)
PDF(1008 KB)
Chinese Pharmaceutical Journal ›› 2013, Vol. 48 ›› Issue (8) : 644-648. DOI: 10.11669/cpj.2013.08.018
Original Articles

Determination of Related Substances in Lapatinib Ditosylate Tablets by HPLC

  • LIU Jun-hua, LIANG Xing-hui,WANG Bin-rong
Author information +
History +

Abstract

OBJECTIVE To establish a determination method of the related substances of lapatinib ditosylate tablets by HPLC. METHODS Waters Xterra MS C18 column (4.6 mm×250 mm, 5 μm) was selected; 0.01 mol·L-1 sodium dihydrogen phosphate solution (pH adjusted to 3.2 with phosphoric acid) was mobile phase A, acetonitrile was mobile phase B, and gradient elution was used at a flow rate of 1.0 mL·min-1. The detection wavelength was set at 265 nm, and the column temperature was 40 ℃. RESULTS Lapatinib Impurity A, LAPA-2 and LAPA-1 had good linearity in the range of 0.02-8.08, 0.02-8.26 and 0.02-8.29 mg·mL-1, respectively (r ≥ 0.999 9). The limits of quantitation (LOQ) were 1.0, 1.4, and 2.1 ng, respectively. The average recovery (n=9) was in the range of 100.2%-102.9%, and RSDs (n=9) were in the range of 0.02%-0.66%. CONCLUSION The method is simple, accurate, and specific and can quantitatively determine the related substances of lapatinib ditosylate tablets.

Key words

HPLC / lapatinib ditosylate tablet / related substance / lapatinib impurity A

Cite this article

Download Citations
LIU Jun-hua, LIANG Xing-hui,WANG Bin-rong. Determination of Related Substances in Lapatinib Ditosylate Tablets by HPLC[J]. Chinese Pharmaceutical Journal, 2013, 48(8): 644-648 https://doi.org/10.11669/cpj.2013.08.018

References

ZHAN Q. Lapatinib in breast cancer treatment . J Int Oncol(国际肿瘤学杂志),2007,34(8):596-599.
SFDA CDE.Technical guidelines for chemical drug impurities(化学药物杂质研究的技术指导原则).SFDA CDE,2007.http://www.cde.org.cn/attachmentout.do?mothed=list&id=161.
GlaxoSmithKline. . FDA,2010.http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s3s6lbl.pdf.
PDF(1008 KB)

Accesses

Citation

Detail

Sections
Recommended

/